Summary

ACH-3102 is a second-generation hepatitis C virus (HCV) nonstructural 5A (NS5A) protein inhibitor with potent activity against HCV genotype (GT)-1 through GT-6. An ongoing phase 2 open-label study evaluated the safety and efficacy of 8 and 6 weeks of ACH-3102 plus sofosbuvir therapy in treatment-naïve patients with chronic HCV GT-1 infection, as discussed in this article.